Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s376, 2024. DOI: 10.25251/skin.8.supp.376. Disponível em: https://skin.dermsquared.com/skin/article/view/2679. Acesso em: 18 apr. 2026.